(Q46294694)

English

ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Tong Zhu

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Walid M Awni

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Balakrishna Hosmane

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Maureen T Kelly

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Darryl J Sleep

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

James C Stolzenbach

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Katty Wan

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Titus O Chira

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Rajendra S Pradhan

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

publication date

24 October 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

49

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

63-71

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Taking aim at HDL-C. Raising levels to reduce cardiovascular risk

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Effectiveness of statin therapy in adults with coronary heart disease.

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Gemfibrozil greatly increases plasma concentrations of cerivastatin

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

1 reference

https://api.crossref.org/works/10.1177%2F0091270008325671

21 January 2018

Identifiers

10.1177/0091270008325671

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18952910

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46294694&oldid=2143364219"